<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272372</url>
  </required_header>
  <id_info>
    <org_study_id>LET</org_study_id>
    <nct_id>NCT04272372</nct_id>
  </id_info>
  <brief_title>Lymphedema Treatment Registry</brief_title>
  <official_title>Multi Center Lymphedema Treatment Registry (LET) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Turkish Lymphedema Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turkish Breast Heath Working Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ege University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with breast cancer related lymphedema (clinical stage 0-2) will include in this
      study. Patients will take their demographic and clinical history and will evaluate with
      measurements of extremity volumes, body mass index, quality of life status and image studies
      (lymphoscintigraphy, Ultrasonography (USG), Indocyanine Green (ICG) Lymphograph or magnetic
      resonance imaging (MRI)) before and after the complete decongestive therapy. Outcome
      measurements such as limb volume, quality of life questionnaire and USG will repeat every
      6,12,18, 24 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with breast cancer related lymphedema (clinical stage 0-2) will include in this
      study. Patients will take their demographic and clinical history and will evaluate with
      measurements of extremity volumes, body mass index, quality of life status and image studies
      (lymphoscintigraphy, USG, ICG or MRI) before and after the complete decongestive therapy
      (CDT). Outcome measurements such as limb volume, quality of life questionnaire and USG will
      repeat every 6,12,18, 24 months.

      Group 1: CDT Group 2: CDT + PO ketoprofen +Local ketoprofen gel Group 3: CDT + Local
      ketoprofen gel
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Limb Volume</measure>
    <time_frame>6,12,18, 24 months</time_frame>
    <description>Volume measurements will take using ulnar styloid process as a index point, and circumferential measurements will take with 5 cm spaces from distal to the proximal. Using a computer programme (Limb Volumes Professional version 5.0), the total volume of the arm is calculate and record before and after the treatment for both arms.
All patients' measurements before and after complete decongestive therapy will take by the same researcher. Volume changes will be evaluated at the 6th, 12th, 18th and 24.th months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life status: Lymphedema Quality of Life Questionnaire-Arm (LYMQOL-ARM)</measure>
    <time_frame>6,12,18, 24 months</time_frame>
    <description>LYMQOL-ARM questionnaire: The LYMQOL-Arm has been developed to assess the impact of lymphedema of the arms on the QoL of the patients. It consists of four domains with 28 items. These domains are symptoms, appearance, function, and mood. The answers were evaluated on a four-point Likert scale (1= not at all 2= a little, 3= quite a bit, 4= a lot). Each item received a score between 1 and 4, with higher scores indicating a worse QoL. Domain totals were calculated by adding the individual scores and dividing the total by the number of questions answered (If &gt;50% of questions per domain were not answered this cannot be calculated
*and =0). If the item was not scored and left blank or not applicable, this was scored with a 0. The four domains and their corresponding questions are: Function 1 (a-h), 2,3, Appearance 4,5,6,7,8 Symptoms 9,10,11,12,13,14 and Emotion 15,16,17,18,19,20. Overall QoL (Q21) is scored as the value marked by the patient, between 0-10.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer Lymphedema</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Complete Decongestive Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Complete Decongestive Therapy + PO Ketoprofen + Local ketoprofen gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Complete Decongestive Therapy + Local Ketoprofen gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoprofen</intervention_name>
    <description>PO and local therapy</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Ketoprofen topical</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Lyymphedema patients with breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer

          -  Lymphedema more than 6 months

          -  Lymphedema stage 0-2

          -  Completed treatment (CT-RT)

        Exclusion Criteria:

          -  Stage 3 lymphedema

          -  Cardiovasculary disease

          -  Hepatic disease

          -  Kidney disease

          -  Cerebrovascular event

          -  Metastasis

          -  Gastritis

          -  Infection

          -  Smoking

          -  Active cancer

          -  Bleeding history
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atilla Soran</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <results_reference>
    <citation>Forte AJ, Boczar D, Huayllani MT, Lu X, McLaughlin SA. Pharmacotherapy Agents in Lymphedema Treatment: A Systematic Review. Cureus. 2019 Dec 5;11(12):e6300. doi: 10.7759/cureus.6300. Review.</citation>
    <PMID>31815082</PMID>
  </results_reference>
  <results_reference>
    <citation>Rockson SG, Tian W, Jiang X, Kuznetsova T, Haddad F, Zampell J, Mehrara B, Sampson JP, Roche L, Kim J, Nicolls MR. Pilot studies demonstrate the potential benefits of antiinflammatory therapy in human lymphedema. JCI Insight. 2018 Oct 18;3(20). pii: 123775. doi: 10.1172/jci.insight.123775.</citation>
    <PMID>30333315</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakamura K, Radhakrishnan K, Wong YM, Rockson SG. Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. PLoS One. 2009 Dec 21;4(12):e8380. doi: 10.1371/journal.pone.0008380.</citation>
    <PMID>20027220</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ege University</investigator_affiliation>
    <investigator_full_name>Sibel Eyigor</investigator_full_name>
    <investigator_title>MD, Prof</investigator_title>
  </responsible_party>
  <keyword>lymphedema</keyword>
  <keyword>breast cancer</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Breast Cancer Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

